Shanghai Junshi Biosciences Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai and currently employs 2,578 full-time employees. The company went IPO on 2018-12-24. Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The firm's main businesses are the discovery, clinical research and development of innovative drugs. The firm's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The firm is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The firm provides its products for domestic and overseas markets.
01877.HK stock price ended at $21.42 on 星期五, after rising 1.81%
On the latest trading day Feb 13, 2026, the stock price of 01877.HK rose by 1.81%, climbing from $21.00 to $21.42. During the session, the stock saw a volatility of 2.49%, with prices oscillating between a daily low of $20.90 and a high of $21.42. Notably, trading volume dropped by 129.1K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 1.4M shares were traded, equating to a market value of approximately $5.5B.